Death with gene editing therapy of CHD3 mutation

Courtesy of a colleague

The 6-year-old girl tugged on her mother’s hand as they pressed through the doors of the hospital in Shanghai. Behind them, her father rolled a large suitcase with everything the child needed for the weeklong stay. She told her parents it felt like they were going on vacation. In fact, they brought her here for an experimental gene therapy.

The girl was slipping behind her peers in kindergarten. She still spoke in simple sentences and ate with training chopsticks. Underneath it all was a single mutated DNA base, a T that should have been a C.

“Your ‘book’ has a small mistake, which has caused you to have a disease that affects your growth,” read the children’s version of the informed consent form from the hospital. “Over time, it can get more serious.”

Doctors hoped to repair that mistake while her brain was still building itself. It would be a clinical trial of one, funded in part by $860,000 the parents had scraped together from their own savings and from relatives.

The parents felt they were in good hands. Xinhua Hospital, which is affiliated with the Shanghai Jiao Tong University School of Medicine, was acclaimed for its pediatrics department. It was the first Chinese institution to perform open heart surgery on infants, and the first in the country to separate conjoined twins. If all went well, the girl would be the first person in the world to receive a gene-editing therapy directed at the brain. It would rewrite the mutated gene in her neurons, restoring the needed DNA base so she could make a vital protein.

Leading the effort was Zilong Qiu, a neuroscientist at the university’s brain center, the Songjiang Research Institute. At the time, in late March 2025, Qiu was one of several researchers around the world vying to push base editors — a more precise form of the powerful gene editor CRISPR — into custom treatments for children with rare diseases. One month earlier, KJ Muldoon, an infant with a life-threatening metabolic disorder, had quietly received his first intravenous infusion of one such treatment at the Children’s Hospital of Philadelphia.

Although news that base editing saved “Baby KJ” would soon rocket around the world — Science named the feat one of the runners-up for its 2025 Breakthrough of the Year — the story of what happened at Xinhua Hospital has remained hidden. An entry for the study posted to ClinicalTrials.gov has not been updated for more than a year. And when Qiu and his colleagues published proof-of-concept animal studies related to the trial in Nature early this year, they stripped the paper of references to the family and its financial contributions, noting only that “bridging the gap between preclinical research and clinical translation remains a significant challenge.”

That vague language glossed over tragedy: Seven days after the girl’s medical team infused trillions of viruses carrying the recipe for the base editor into her spinal fluid, she died of a severe immune reaction linked to the therapy, Science and Retraction Watch can now reveal.

According to official documents and accounts provided by the girl’s parents, the hospital had allowed Qiu’s experimental treatment to proceed under a regulatory provision that does not require approval from national regulators. The lax oversight of this recent trial and the failure to publicly report the fatality “shows the gap between what is intended and what has been put in place,” says Joy Zhang, a sociologist at the University of Kent who has written about the pervasive culture of secrecy in Chinese scientific institutions.

Seven experts in fields including genetics, virology, and bioethics who reviewed details of the Nature study and the clinical trial for Science and Retraction Watch expressed concern that Qiu and his team downplayed the trial’s risks in describing them to the parents, overlooked safety signals in animal studies, and proceeded even though success was unlikely. “This shouldn’t have gone to trial,” says Steven Gray of the University of Texas Southwestern Medical Center, who develops viruses for gene therapy.

Gray and several of the other experts are calling for a full review of the images and other data in submitted and published versions of the Nature paper and full disclosure of the study’s funding. Some of the issues might warrant a retraction, they say. Neither Qiu nor his university or the hospital responded to multiple requests for comment for this story, and Nature says it was not aware of the issues surrounding the clinical trial before it published the group’s paper.

The girl’s parents have decided to tell her story now because they are angry about what they feel is a lack of accountability by the researchers and the institutions. “Learning the reality of these missing safeguards has fundamentally changed how we now view the entire project,” says the father, a software engineer. “We did not realize how unusual and dangerous many of the arrangements were.”

https://retractionwatch.com/2026/07/23/exclusive-death-gene-editing-trial-china-nature-science-investigation/#more-135456

See: https://www.science.org/content/article/exclusive-death-girl-chinese-gene-editing-trial-was-never-made-public

Yang K, Li WK, Geng YX, Zhang SQ, Wu SH, Cheng YB, Wang JW, Xu ZK, Wang WX, Zhang TY, Wang PY, Yuan YT, Fan J, Wu J, Xu RC, Zhang YF, Tao GJ, Li ZH, Lin CX, Li TS, Zhang XY, Li J, Zhang R, Yang WX, Wen JS, Yang ZY, Gong L, Zeng W, Du AL, Li JS, Li F, Cheng TL, Qiu Z. In vivo base editing of Chd3 rescues behavioural abnormalities in mice. Nature. 2026 Mar;651(8106):785-795. doi: 10.1038/s41586-026-10113-6. Epub 2026 Feb 18. PMID: 41708849; PMCID: PMC12999480.

Abstract

Neurodevelopmental disorders that arise from de novo mutations in chromatin-remodelling genes lack targeted treatments. Snijders Blok-Campeau syndrome (SNIBCPS)1, which is caused by pathogenic variants in CHD3, manifests with intellectual disability, autistic-like behaviours and motor deficits2. Whether somatic gene correction can reverse such phenotypes in vivo remains unknown. Here we show that modelling the recurrent CHD3 variant p.R1025W in a humanized mouse model (Chd3hR1025W/+) recapitulates key features of SNIBCPS, including reduced CHD3 protein levels and abnormalities in social communication, cognition and motor coordination. We engineered a TadA-embedded adenine base editor (TeABE) and delivered it brain-wide using a dual adeno-associated virus (AAV) system and achieved efficient on-target A•T-to-G•C correction across multiple cortical and hippocampal regions with minimal bystander activity. This intervention restored CHD3 levels and ameliorated behavioural abnormalities in vivo. Furthermore, intrathecal dual AAV delivery in nonhuman primates resulted in widespread neuronal transduction and efficient TeABE reconstitution, a result that supports its translational feasibility. These findings establish in vivo base editing as a viable therapeutic approach for CHD3-related neurodevelopmental disease. More broadly, they demonstrate that precise single-base correction in the postnatal brain can restore protein dosage and function, thereby offering a framework for the treatment of monogenic neurodevelopmental disorders.

Carbamoyl phosphate synthetase 1 treated with a customized CRISPR gene editing therapy 2

In a historic medical breakthrough, a child diagnosed with a rare genetic disorder has been successfully treated with a customized CRISPR gene editing therapy by a team at Children’s Hospital of Philadelphia (CHOP) and Penn Medicine. The infant, KJ, was born with a rare metabolic disease known as severe carbamoyl phosphate synthetase 1 (CPS1) deficiency. After spending the first several months of his life in the hospital, on a very restrictive diet, KJ received the first dose of his bespoke therapy in February 2025 between six and seven months of age. The treatment was administered safely, and he is now growing well and thriving.

KJ was only days old when he was diagnosed with a rare metabolic disorder and transferred to Children's Hospital of Philadelphia where doctors were actively researching new cell and gene therapies.

The case is detailed today in a study published by The New England Journal of Medicine and was presented at the American Society of Gene & Cell Therapy Annual Meeting in New Orleans. This landmark finding could provide a pathway for gene editing technology to be successfully adapted to treat individuals with rare diseases for whom no medical treatments are available.

“Years and years of progress in gene editing and collaboration between researchers and clinicians made this moment possible, and while KJ is just one patient, we hope he is the first of many to benefit from a methodology that can be scaled to fit an individual patient’s needs,” said Rebecca Ahrens-Nicklas, MD, PhD, director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program (GTIMD) at Children’s Hospital of Philadelphia and an assistant professor of Pediatrics in the Perelman School of Medicine at the University of Pennsylvania.

CRISPR (clustered regularly interspaced short palindromic repeats)-based gene editing can precisely correct disease-causing variants in the human genome. Gene editing tools are incredibly complex and nuanced, and up to this point, researchers have built them to target more common diseases that affect tens or hundreds of thousands of patients, such as the two diseases for which there currently are U.S. Food and Drug Administration-approved therapies, sickle cell disease and beta thalassemia. However, relatively few diseases benefit from a “one-size-fits-all” gene editing approach since so many disease-causing variants exist. Even as the field advances, many patients with rare genetic diseases – collectively impacting millions of patients worldwide – have been left behind.

Researchers and clinicians at CHOP and Penn began collaborating to study the feasibility of creating customized gene editing therapies for individual patients in 2023.

A Collaborative Effort

Ahrens-Nicklas and Kiran Musunuru, MD, PhD, the Barry J. Gertz Professor for Translational Research in Penn’s Perelman School of Medicine, who are co-corresponding authors on the published report, began collaborating to study the feasibility of creating customized gene editing therapies for individual patients in 2023, building upon many years of research into rare metabolic disorders, as well as the feasibility of gene editing to treat patients. Both are members of the NIH funded Somatic Cell Genome Editing Consortium, which supports collaborative genome editing research.

Ahrens-Nicklas and Musunuru decided to focus on urea cycle disorders. During the normal breakdown of proteins in the body, ammonia is naturally produced. Typically, our bodies know to convert the ammonia to urea and then excrete that urea through urination. However, a child with a urea cycle disorder lacks an enzyme in the liver needed to convert ammonia to urea. Ammonia then builds up to a toxic level, which can cause organ damage, particularly in the brain and the liver.

After years of preclinical research with similar disease-causing variants, Ahrens-Nicklas and Musunuru targeted KJ’s specific variant of CPS1, identified soon after his birth. Within six months, their team designed and manufactured a base editing therapy delivered via lipid nanoparticles to the liver in order to correct KJ’s faulty enzyme. In late February 2025, KJ received his first infusion of this experimental therapy, and since then, he has received follow-up doses in March and April 2025. In the newly published New England Journal of Medicine paper, the researchers, along with their academic and industry collaborators, describe the customized CRISPR gene editing therapy that was rigorously yet speedily developed for administration to KJ.

As of April 2025, KJ had received three doses of the therapy with no serious side effects. In the short time since treatment, he has tolerated increased dietary protein and needed less nitrogen scavenger medication. He also has been able to recover from certain typical childhood illnesses like rhinovirus without ammonia building up in his body. Longer follow-up is needed to fully evaluate the benefits of the therapy.

“While KJ will need to be monitored carefully for the rest of his life, our initial findings are quite promising,” Ahrens-Nicklas said.

“We want each and every patient to have the potential to experience the same results we saw in this first patient, and we hope that other academic investigators will replicate this method for many rare diseases and give many patients a fair shot at living a healthy life,” Musunuru said. “The promise of gene therapy that we’ve heard about for decades is coming to fruition, and it’s going to utterly transform the way we approach medicine.”

A Future for KJ

Typically, patients with CPS1 deficiency, like KJ, are treated with a liver transplant. However, for patients to receive a liver transplant, they need to be medically stable and old enough to handle such a major procedure. During that time, episodes of increased ammonia can put patients at risk for ongoing, lifelong neurologic damage or even prove fatal. Because of these threats to lifelong health, the researchers knew that finding new ways to treat patients who are too young and small to receive liver transplants would be life-changing for families whose children faced this disorder.

“We would do anything for our kids, so with KJ, we wanted to figure out how we were going to support him and how we were going to get him to the point where he can do all the things a normal kid should be able to do,” his mother, Nicole Muldoon, said. “We thought it was our responsibility to help our child, so when the doctors came to us with their idea, we put our trust in them in the hopes that it could help not just KJ but other families in our position.”

“We’ve been in the thick of this since KJ was born, and our whole world’s been revolving around this little guy and his stay in the hospital,” his father, Kyle Muldoon, said. “We’re so excited to be able to finally be together at home so that KJ can be with his siblings, and we can finally take a deep breath.”

This study was supported by grants from the National Institutes of Health Somatic Cell Genome Editing Program (U01TR005355, U19NS132301), as well as additional National Institutes of Health grants (R35HL145203, U19NS132303, DP2CA281401, P01HL142494). In-kind contributions were made by Acuitas Therapeutics, Integrated DNA Technologies, Aldevron, and Danaher Corporation. Additional funding was provided by the CHOP Research Institute’s Gene Therapy for Inherited Metabolic Disorders Frontier Program.

https://www.chop.edu/news/worlds-first-patient-treated-personalized-crispr-gene-editing-therapy-childrens-hospital

Musunuru K, Grandinette SA, Wang X, Hudson TR, Briseno K, Berry AM, Hacker JL, Hsu A, Silverstein RA, Hille LT, Ogul AN, Robinson-Garvin NA, Small JC, McCague S, Burke SM, Wright CM, Bick S, Indurthi V, Sharma S, Jepperson M, Vakulskas CA, Collingwood M, Keogh K, Jacobi A, Sturgeon M, Brommel C, Schmaljohn E, Kurgan G, Osborne T, Zhang H, Kinney K, Rettig G, Barbosa CJ, Semple SC, Tam YK, Lutz C, George LA, Kleinstiver BP, Liu DR, Ng K, Kassim SH, Giannikopoulos P, Alameh MG, Urnov FD, Ahrens-Nicklas RC. Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease. N Engl J Med. 2025 Jun 12;392(22):2235-2243. doi: 10.1056/NEJMoa2504747. Epub 2025 May 15. PMID: 40373211; PMCID: PMC12713542.

Abstract

Base editors can correct disease-causing genetic variants. After a neonate had received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency, a disease with an estimated 50% mortality in early infancy, we immediately began to develop a customized lipid nanoparticle-delivered base-editing therapy. After regulatory approval had been obtained for the therapy, the patient received two infusions at approximately 7 and 8 months of age. In the 7 weeks after the initial infusion, the patient was able to receive an increased amount of dietary protein and a reduced dose of a nitrogen-scavenger medication to half the starting dose, without unacceptable adverse events and despite viral illnesses. No serious adverse events occurred. Longer follow-up is warranted to assess safety and efficacy. (Funded by the National Institutes of Health and others.).

See: https://childnervoussystem.blogspot.com/2025/05/carbamoyl-phosphate-synthetase-1.html

Ehlers-Danlos syndrome and small fiber neuropathy

Dell'Aversana D, Provitera V, Trinchillo A, Masciarelli F, Tozza S, Caporaso G, Vitale F, Borreca I, Areniello AR, Ciccarelli G, Esposito G, Iodice R, Dubbioso R, Manganelli F, Santoro L, Castori M, Nolano M. Distinct sensory and autonomic involvement in hypermobile Ehlers-Danlos syndrome compared with idiopathic small fiber neuropathy: a multimodal study. Sci Rep. 2026 Jul 3. doi: 10.1038/s41598-026-60461-6. Epub ahead of print. PMID: 42399338.

Abstract

Hypermobile Ehlers-Danlos syndrome (hEDS), frequently presents with pain and autonomic symptoms suggestive of small fiber neuropathy (SFN). However, systematic comparisons between hEDS and idiopathic SFN (iSFN) using combined clinical, functional, and morphological approaches are lacking. We prospectively studied a population of SFN patients who also fulfilled the 2017 criteria for hEDS (hEDS/SFN) and compared them with a group of iSFN patients of similar age. All underwent SFN-Symptoms Inventory Questionnaire (SFN-SIQ), Douleur Neuropathique 4 (DN4), and the Composite Autonomic Symptom Score-31 (COMPASS-31) questionnaires, quantitative sensory testing (QST), autonomic testing (cardiovascular reflexes, sympathetic skin response, dynamic sweat test), and skin biopsy from leg, thigh, and fingertip. Clinical, morphological and functional data were compared with our normative dataset and between the two patient groups. 35 hEDS/SFN and 38 iSFN patients were included in the study. hEDS/SFN patients had earlier symptom onset (19.5 ± 5.9 years vs. 35.2 ± 8.7 years, p < 0.001), more generalized distribution, and higher COMPASS-31 scores (54.3 ± 16.9 vs. 33.9 ± 19.4 p < 0.01), particularly in orthostatic intolerance, gastrointestinal, and urinary domains. Postural Orthostatic Tachycardia Syndrome (POTS) was present in half of hEDS/SFN patients while it was not found in iSFN (51.5% vs. 0.0%). Skin biopsy revealed similar intraepidermal nerve fiber loss in both groups, but hEDS had greater autonomic fiber loss (p < 0.05). Small fiber involvement in hEDS is characterized by earlier onset, more generalized pain and severe autonomic symptoms, and higher autonomic morpho-functional impairment compared with iSFN. Systematic autonomic assessment and targeted management should be considered in this population.

Novak P, Systrom DM, Marciano SP, Witte A, Warren A, Felsenstein D, Giannetti MP, Hamilton MJ, Nicoloro-SantaBarbara J, Castells M, Farhad K, Pilgrim DM, Mullally WJ, Fishman MC, Milunsky JM, Milunsky A, Krier J. Hypermobile Ehlers-Danlos Syndrome: Cerebrovascular, Autonomic and Neuropathic Features. Am J Med Open. 2025 Jul 18;14:100111. doi: 10.1016/j.ajmo.2025.100111. PMID: 40843452; PMCID: PMC12365377.

Abstract

Background: Hypermobile Ehlers-Danlos syndrome (hEDS) affects multiple systems, but comprehensive evaluations of a larger sample of hEDS patients are lacking. The objective of this study was to describe cerebrovascular, autonomic, and neuropathic features of hEDS.

Methods: This retrospective case-control study was conducted at Brigham and Women's Faulkner Hospital between 2016-2023. Data from hEDS patients who completed autonomic testing and skin biopsies were analyzed. Outcome measures include validated surveys (Survey of Autonomic Functions, Neuropathy Total Symptom Score-6 (SAS)) and autonomic function testing (Valsalva maneuver, deep breathing, head-up tilt and sudomotor), cerebrovascular (cerebral blood flow velocity (CBFv) in the middle cerebral artery), respiratory (capnography), and neuropathic (skin biopsies for assessment of small fiber neuropathy) testing and inflammatory/ autoimmune markers.

Results: Total 270 hEDS patients were analyzed and compared to 29 healthy controls. Common hEDS complaints (prevalence > 90% ) were orthostatic sudomotor, vasomotor, gastrointestinal, and pain. Orthostatic cerebral blood flow velocity was reduced in 79% of hEDS and correlated with orthostatic dizziness. The head-up tilt test revealed postural tachycardia syndrome (prevalence 33%), hypocapnic cerebral hypoperfusion (22%), orthostatic cerebral hypoperfusion syndrome (18%), and neurogenic orthostatic hypotension (9%). Widespread but mild autonomic failure was present in 90% of hEDS patients on autonomic testing. Small fiber neuropathy using structural criteria was detected in 64%, and using combined structural and functional criteria in 82%.

Conclusions: This study provided evidence of cerebrovascular dysregulation with reduced orthostatic cerebral blood flow velocity associated with symptoms of cerebral hypoperfusion, frequent small fiber neuropathy, and widespread but mild autonomic failure in hEDS.

Igharo D, Thiel JC, Rolke R, Akkaya M, Weis J, Katona I, Schulz JB, Maier A. Skin biopsy reveals generalized small fibre neuropathy in hypermobile Ehlers-Danlos syndromes. Eur J Neurol. 2023 Mar;30(3):719-728. doi: 10.1111/ene.15649. Epub 2022 Dec 13. PMID: 36437696.

Abstract

Background and purpose: Ehlers-Danlos syndromes are hereditary disorders of connective tissue that are characterized by joint hypermobility, skin hyperextensibility and tissue fragility. The most common subtype is the hypermobile type. In addition to symptoms of small fibre neuropathy (SFN) due to damage to the small peripheral nerve fibres, with degeneration of the distal nerve endings, autonomic disorders such as postural tachycardia syndrome (PoTS) are frequently reported features in patients with hypermobile Ehlers-Danlos syndrome (hEDS). To date, the underlying pathophysiological mechanisms are still not completely understood.

Study purpose: To better understand pathophysiological mechanisms of small fiber neuropathy and autonomic neuropathy in hypermobile Ehlers-Danlos Syndromes.

Methods: We prospectively investigated 31 patients with hEDS compared to 31 healthy controls by using skin biopsy, quantitative sensory testing, tilt-table testing, the painDetect, Small Fibre Neuropathy Screening List and the COMPASS-31 (Composite Autonomic Symptom Score 31) questionnaire.

Results: Nineteen (61%) patients with hEDS were diagnosed with SFN, and 10 (32%) fulfilled the criteria for PoTS. Patients with hEDS had significantly higher heart rates than controls. According to quantitative sensory testing, these patients had generalized thermal and tactile hypesthesia. Skin biopsy revealed significantly reduced intraepithelial nerve fibre density proximally (thigh) and distally (lower leg) in patients compared to controls. This was consistent with various complaints of pain and sensory disturbances in both the proximal and distal body regions.

Conclusion: These results confirm histologically proven SFN as a common feature in patients with hEDS, revealing a generalized distribution of nerve fibre loss. Regarding the frequently reported autonomic and neuropathic dysfunctions, the findings support SFN as an important, but not the only, underlying pathomechanism.

See: https://childnervoussystem.blogspot.com/2016/10/ehlers-danlos-syndrome-linked-to-small.html

Great experiments 3

Lee HF, Chi CS, Tsai CR, Chen CH, Wang CC. Electroencephalographic features of patients with SCN1A-positive Dravet syndrome. Brain Dev. 2015 Jun;37(6):599-611. doi: 10.1016/j.braindev.2014.10.003. Epub 2014 Oct 27. PMID: 25459968.

Video EEG recording during HWBT (hot water bathing test) was performed after obtaining informed consent from the patients’ parents. After a 20-min routine EEG recording, the patient was requested to remove his or her clothing and then sit in chest above the level of the water. The initial water temperature was around 35–37 C depending on the patient’s preference. Hot water at a temperature of around 55–60 C was collected in a stainless wash basin. The water temperature of the bath tub was increased gradually by means of alternately scooping water out of the bath tub and transferring hot water from the wash basin to the bath tub to raise the water temperature up to a maximum of around 40 C. Simultaneously, water from the bath tub was intermittently poured onto the patient’s shoulders with a small bowl in order to elevate the patient’s body temperature. The patient’s axillary temperature and the water temperature were recorded simultaneously every 10 min during the course of the test. The procedure was discontinued immediately after seizure initiation. In cases where the patient exhibited a seizure during the test, he or she was taken out of the water, placed on a bed, gently dried with a towel, and seizure patterns were then recorded. If no seizure developed, the HWBT was ended after 30 min, and the final axillary and water temperatures were recorded.

Mytinger JR, Weisleder P. E. Steve Roach: Reflections From the Editor-In-Chief of Pediatric Neurology. Pediatr Neurol. 2021 Dec;125:58-60. doi: 10.1016/j.pediatrneurol.2021.09.006. PMID: 34715988.

What is the most chillingly inappropriate manuscript that was submitted during your term as the journal's editor?

One alarming manuscript summarized a study that attempted to verify the clinical observation that increased temperature can trigger seizures in children with Dravet syndrome by immersing children in a hot water bath designed to raise their body temperature to see if it would trigger a seizure. The children who experienced a seizure were then removed from the bath so the seizure could be filmed and characterized, with no stated plan for intervening should a prolonged seizure occur. All of this, naturally, without mention of an institutional review board approval!

(The Lee article is not necessarily the one referred to in the Mytinger article. I could not confirm.)

Pediatric headache: A comprehensive review

Wander A, Meena AK, Choudhary PK, Peer S, Singh R. Pediatric Headache: A Comprehensive Review. Ann Child Neurol. 2024;32(4):207-218.

Abstract

Pediatric headache is a common condition that often results in frequent outpatient visits. There are two broad etiological groups of headaches—primary and secondary headaches—with the former being more prevalent. Migraine, a type of primary headache, shares similarities with those experienced by adults, albeit with some variations in diagnostic criteria. The secondary causes of headache should be differentiated from the primary headaches with proper clinical evaluation and focussed investigations. The management of migraine focusses on lifestyle modifications, behavioral therapy, and pharmacotherapy for acute episodes and long-term preventive therapy. There are many novel promising treatment modalities. This review article provides an overview of pediatric headache epidemiology, classification, and pathophysiology and then elaborates on management and prevention strategies.

From the article:

1. Etiology

Headaches in children can be categorized into primary, where pain is a result of the headache condition itself, and secondary, where pain serves as a symptom of an underlying condition. Migraine and tension-type headaches are the most frequently encountered types of primary headaches in children. Cluster headache, a type of primary headache in children, exhibits similar characteristics to headaches in adults but is rare among young children. Upper respiratory tract infections are the commonest cause of secondary headaches that prompt emergency visits. Meningitis, hydrocephalus, and intracranial tumours are common etiologies of life-threatening headache in children. Frequently, no diagnosis can be reached despite an extensive evaluation. In a study involving 48,575 children aged 5 to 17 years who had headache disorders, about 19% were identified with primary headaches, 1.1% were diagnosed with secondary headaches, and 79.7% did not receive a formal diagnosis.

2. Pathophysiology

The pathophysiology of headaches is intricate, with genetic and environmental factors playing crucial roles in the development of migraine, tension-type headache, and cluster headache. However, identifying the specific genes involved has proven to be a challenging task. Familial hemiplegic migraine, which is linked to mutations in the calcium voltage-gated channel subunit alpha1 A (CACNA1A), ATPase Na+/K+ transporting subunit alpha 2 (ATP1A2), and sodium voltage-gated channel alpha subunit 1 (SCN1A) genes, and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), which is associated with a notch receptor 3 (NOTCH3) gene mutation, stand out as the most extensively studied headache disorders with a genetic foundation.

The vascular theory of migraines, according to which migraine stems from blood vessel dilation and that the aura is a result of vasoconstriction, is now deemed invalid, as evidenced by magnetic resonance angiography studies. A typical migraine episode consists of four phases: the prodromal or premonitory phase, the aura phase, the headache phase, and the post-dromal phase. The premonitory phase is characterized by irritability, fatigue, difficulty in concentration, nausea, or pallor. Functional neuroimaging studies suggest involvement of the hypothalamus in the premonitory phase, as well as during the migraine attack phase. The migraine aura constitutes a reversible neurological phenomenon impacting approximately one-third of all migraine sufferers and occasionally overlapping with the headache phase. The underlying mechanism of this phase is thought to involve cortical spreading depolarization (CSD) across the cortex. CSD is marked by a brief excitation period, followed by a prolonged depression of cortical activity. Originating from the occipital lobes, it propagates anteriorly, dissipates at the central sulcus, and influences neurotransmitter levels, ionic balance, and blood flow. The headache phase is characterized by the activation of the trigeminocervical complex. Neuropeptides, particularly calcitonin gene-related peptide (CGRP), are involved in trigeminal activation and have emerged as a potential target for therapeutic interventions in migraine patients. 

The development of cluster headaches involves interactions among the trigemino-vascular pathway, trigeminal autonomic reflex, hypothalamus, and the neuropeptides CGRP and pituitary adenylate cyclase-activating polypeptide. In tension-type headaches, the pain is thought to stem from myofascial structures and is heightened by central sensitization mechanisms. This central sensitization involves an imbalance in neurotransmitters such as CGRP, nitric oxide, neurokinin-A, glutamate, substance-P, serotonin, and endogenous peptide systems...

Conclusion

Pediatric headache is a prevalent condition in children, leading to substantial morbidity and frequent healthcare visits. The primary culprits are often primary headaches and acute viral infections. The initial assessment is essential for identifying potential warning signs, excluding secondary or life-threatening causes of headaches, and minimizing unnecessary investigations. Migraine is the most significant and common type of headache in children and adolescents. Prompt acute management of migraines involves supportive care and analgesics, but there is a lack of clear evidence-based recommendations for preventive therapy in children, highlighting a need for further research in this area. Newer modalities including non-invasive neuro-simulation botulinum toxin and CGRP antagonists are promising and emerging therapies. 

Phenomenology and clinical relevance of minor neurological signs in child neurology

Magostini F, Paris G, Capuano A. Phenomenology and clinical relevance of minor neurological signs in child neurology and psychiatry. Front Neurol. 2026 May 8;17:1761780. doi: 10.3389/fneur.2026.1761780. PMID: 42180220; PMCID: PMC13193831.

Abstract

Minor Neurological Signs, also referred to as neurological soft signs, are subtle abnormalities detected during neurological examination that do not meet criteria for major focal deficits. They are increasingly considered indicators of variability in neurodevelopment, likely reflecting differences in sensorimotor integration and maturation of cortico–subcortical networks. This mini review summarizes current evidence on the phenomenology, neurobiological correlates, and clinical relevance of MNS in child neurology and psychiatry. MNS include motor features such as overflow movements, dysmetria, dysrhythmia, and mild alterations in coordination, tone, and balance. Their assessment relies on standardized, developmentally appropriate tools that support identification of distinct patterns of dysfunction. MNS are frequently reported in neurodevelopmental and psychiatric conditions. While not diagnostically specific, they have been associated with symptom severity and functional outcomes. Further longitudinal and integrative studies are needed to clarify their developmental trajectories, neurobiological mechanisms, and potential clinical utility.

From the article:

In line with the movement disorders classification and subsequent classification efforts in the field of minor neurological signs, we can identify the following phenomenological categories:

1) Hyperkinetic movement disorders: these are characterized by involuntary movements, primarily manifesting as tremors, choreiform movements, and dystonic postures.

a) Tremor: defined as a rhythmic, oscillatory movement of a body part, resulting from alternating or synchronous contractions of antagonist muscles, and may occur at rest, during posture, or during action.

b) Choreiform movements: frequently described as “dance-like” or “piano playing movements”, consist of brief, irregular, non-rhythmic, and unpredictable movements that flow randomly from one body part to another, predominantly affecting the distal extremities. These movements are not suppressible and are characterized by variability in timing, amplitude, and distribution.

c) Dystonia: characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive movements or postures. These movements are typically patterned, twisting, and may be triggered or worsened by voluntary action.

2) Overflow movements: these refer to involuntary movements of body parts that are not necessary to perform a motor task effectively. Notable examples include contralateral motor overflow and mirror movements.

3) Dysmetria: this is identified as an inability to control the trajectory of purposeful movements, particularly concerning coordination of the extremities.

4) Miscellaneous disturbances: this category includes mild alterations in muscle tone, abnormalities in balance and gait (e.g., tandem gait), lateralization and dysrhythmia (an impairment of motor timing and of the ability to generate, maintain, or synchronize temporal sequences of movement, resulting in irregularity in rhythmic execution and coordination).

Although individually non-specific, these signs reflect variations in the organization and integration of distributed sensorimotor networks and are commonly observed within the spectrum of minor neurological signs...

The systematic observation of MNS provides clinically relevant information on the functional organization of developing neural systems involved in motor control and sensory integration. Rather than directly informing etiology, MNS can be understood as observable markers of variability in the organization and functioning of subcortical and cortico–subcortical systems. However, their clinical relevance is often underestimated and not always fully recognized during assessment, despite their potential to support early identification of risk in children who do not yet meet full diagnostic criteria but present emerging signs of neurodevelopmental vulnerability.

In the clinical context, MNS should be conceptualized as structured, domain-specific configurations of signs that support the identification of neurodevelopmental subgroups. MNS can be interpreted as intermediate phenotypes along a spectrum that includes, on one end, transient maturational variations and, on the other, conditions characterized by structural and persistent deficits, such as cerebral palsy.

The systematic assessment of MNS using standardized and specific tools is essential to clinical practice. Recognizing MNS as central components of neurodevelopmental assessment may improve early diagnosis, refine phenotypic stratification, and support the implementation of earlier and more tailored interventions in neurodevelopmental disorders.

Multiple genetic etiologies causing Dandy-Walker variant with microcephaly, epilepsy, and global developmental delay.

Zhang LB, Wu YY, Qiu DJ, Li WB, Ye ZL. Child Neurology: Multiple Genetic Etiologies Causing Dandy-Walker Variant With Microcephaly, Epilepsy, and Global Developmental Delay. Neurology. 2026 Apr 14;106(7):e214793. doi: 10.1212/WNL.0000000000214793. Epub 2026 Mar 6. PMID: 41791021.

Abstract

Dandy-Walker syndrome is typically characterized by near-complete cerebellar vermis agenesis, enlarged posterior fossa, and dilated fourth ventricle. By contrast, Dandy-Walker variant (DWv) shows milder features, typically characterized by partial agenesis of the cerebellar vermis, mild enlargement of the posterior fossa, and variable dilation of the fourth ventricle. Both conditions are usually associated with normal or enlarged head circumference. We report a 16-month-old girl presenting with congenital microcephaly, frequent seizures, and severe global developmental delay. Brain MRI revealed findings consistent with DWv, which did not explain the severity of her clinical symptoms or her microcephaly. Chromosomal microarray analysis revealed multiple regions of homozygosity on chromosome 11, indicating potential recessive inheritance; karyotype analysis and mitochondrial testing showed no clear etiology. Trio-based whole-exome sequencing identified a heterozygous variant (NM_021096.4:c.4891T>A/p.Phe1631Ile) in CACNA1I and a homozygous variant (NM_002335.4:c.1310C>T/p.Thr437Met) in LRP5. Variants in CACNA1I are associated with neurodevelopmental disorders, including epilepsy and developmental delay, while variants in LRP5 are linked to osteoporosis and microcephaly. Based on the clinical presentation and molecular findings, we hypothesize that both variants contributed to the patient's complex phenotype. This case highlights that in patients with unusually severe or atypical manifestations, the possibility of multiple genetic pathogenic contributions should be considered, and comprehensive genomic evaluation is essential for accurate diagnosis and management.

Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient

Cellucci T, Van Mater H, Graus F, Muscal E, Gallentine W, Klein-Gitelman MS, Benseler SM, Frankovich J, Gorman MP, Van Haren K, Dalmau J, Dale RC. Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurol Neuroimmunol Neuroinflamm. 2020 Jan 17;7(2):e663. doi: 10.1212/NXI.0000000000000663. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2020 Apr 15;7(4):e730. doi: 10.1212/NXI.0000000000000730. PMID: 31953309; PMCID: PMC7051207.

Abstract

Objective: Autoimmune encephalitis (AE) is an important and treatable cause of acute encephalitis. Diagnosis of AE in a developing child is challenging because of overlap in clinical presentations with other diseases and complexity of normal behavior changes. Existing diagnostic criteria for adult AE require modification to be applied to children, who differ from adults in their clinical presentations, paraclinical findings, autoantibody profiles, treatment response, and long-term outcomes.

Methods: A subcommittee of the Autoimmune Encephalitis International Working Group collaborated through conference calls and email correspondence to consider the pediatric-specific approach to AE. The subcommittee reviewed the literature of relevant AE studies and sought additional input from other expert clinicians and researchers.

Results: Existing consensus criteria for adult AE were refined for use in children. Provisional pediatric AE classification criteria and an algorithm to facilitate early diagnosis are proposed. There is also discussion about how to distinguish pediatric AE from conditions within the differential diagnosis.

Conclusions: Diagnosing AE is based on the combination of a clinical history consistent with pediatric AE and supportive diagnostic testing, which includes but is not dependent on antibody testing. The proposed criteria and algorithm require validation in prospective pediatric cohorts.

Last American to use an iron lung dies

A 78-year-old Oklahoma woman who was diagnosed with polio as a child and was the last American to rely on an iron lung to live has died.

Martha Lillard found out she had the once-feared disease when she was 5 years old, which left her paralyzed from the neck down, and required her to use the machine to help her breathe while she slept.

Lillard contracted COVID-19 twice during the pandemic, which left her in the machine nearly 24 hours a day.

"They told her she wasn't supposed to live past 20 years old," her younger sister, Cindy McVey, told The Associated Press on Friday. "She had the enthusiasm and the drive to continue living and make the best of her life."

Despite having polio, Lillard was able to go to school two hours a day as a child, and she had tutors the rest of the time. She also used an intercom phone system that allowed her to interact with her teachers and classmates from home.

Lillard was even able to take road trips as a child because of a custom trailer that could accommodate the iron lung and her father making sure their hotels had wide enough doors for the machine.

An iron lung is a negative-pressure ventilator that helps a patient with paralyzed lung muscles breathe.

The disease once caused thousands of cases of paralysis in children during outbreaks each year in the first part of the 20th century before a vaccine became available in 1955.

By 1979, polio was considered eliminated in the U.S.

Later, Lillard was able to regain the use of her left arm and legs through therapy and was even able to drive for a time.

She lived independently for many years, even getting married earlier this year to a man from Egypt she corresponded with for two decades after he was able to obtain a visa.

"They were really soul mates," McVey said. "He's extremely brokenhearted."

Lillard, who wrote poetry and volunteered with the Humane Society, according to her sister, had just 25% lung capacity before she was diagnosed with COVID.

https://www.foxnews.com/health/last-american-use-iron-lung-dies-78-years-old-childhood-polio-diagnosis

Riboflavin transporter deficiency and energy dysmetabolism

Colasuonno F, Marioli C, Tartaglia M, Bertini E, Compagnucci C, Moreno S. New Insights into the Neurodegeneration Mechanisms Underlying Riboflavin Transporter Deficiency (RTD): Involvement of Energy Dysmetabolism and Cytoskeletal Derangement. Biomedicines. 2022 Jun 6;10(6):1329. doi: 10.3390/biomedicines10061329. PMID: 35740351; PMCID: PMC9219947.

Abstract

Riboflavin transporter deficiency (RTD) is a rare genetic disorder characterized by motor, sensory and cranial neuropathy. This childhood-onset neurodegenerative disease is caused by biallelic pathogenic variants in either SLC52A2 or SLC52A3 genes, resulting in insufficient supply of riboflavin (vitamin B2) and consequent impairment of flavoprotein-dependent metabolic pathways. Current therapy, empirically based high-dose riboflavin supplementation, ameliorates the progression of the disease, even though response to treatment is variable and partial. Recent studies have highlighted concurrent pathogenic contribution of cellular energy dysmetabolism and cytoskeletal derangement. In this context, patient specific RTD models, based on induced pluripotent stem cell (iPSC) technology, have provided evidence of redox imbalance, involving mitochondrial and peroxisomal dysfunction. Such oxidative stress condition likely causes cytoskeletal perturbation, associated with impaired differentiation of RTD motor neurons. In this review, we discuss the most recent findings obtained using different RTD models. Relevantly, the integration of data from innovative iPSC-derived in vitro models and invertebrate in vivo models may provide essential information on RTD pathophysiology. Such novel insights are expected to suggest custom therapeutic strategies, especially for those patients unresponsive to high-dose riboflavin treatments.

Marioli C, Magliocca V, Petrini S, Niceforo A, Borghi R, Petrillo S, La Rosa P, Colasuonno F, Persichini T, Piemonte F, Massey K, Tartaglia M, Moreno S, Bertini E, Compagnucci C. Antioxidant Amelioration of Riboflavin Transporter Deficiency in Motoneurons Derived from Patient-Specific Induced Pluripotent Stem Cells. Int J Mol Sci. 2020 Oct 7;21(19):7402. doi: 10.3390/ijms21197402. PMID: 33036493; PMCID: PMC7582490.

Abstract

Mitochondrial dysfunction is a key element in the pathogenesis of neurodegenerative disorders, such as riboflavin transporter deficiency (RTD). This is a rare, childhood-onset disease characterized by motoneuron degeneration and caused by mutations in SLC52A2 and SLC52A3, encoding riboflavin (RF) transporters (RFVT2 and RFVT3, respectively), resulting in muscle weakness, ponto-bulbar paralysis and sensorineural deafness. Based on previous findings, which document the contribution of oxidative stress in RTD pathogenesis, we tested possible beneficial effects of several antioxidants (Vitamin C, Idebenone, Coenzyme Q10 and EPI-743, either alone or in combination with RF) on the morphology and function of neurons derived from induced pluripotent stem cells (iPSCs) from two RTD patients. To identify possible improvement of the neuronal morphotype, neurite length was measured by confocal microscopy after β-III tubulin immunofluorescent staining. Neuronal function was evaluated by determining superoxide anion generation by MitoSOX assay and intracellular calcium (Ca2+) levels, using the Fluo-4 probe. Among the antioxidants tested, EPI-743 restored the redox status, improved neurite length and ameliorated intracellular calcium influx into RTD motoneurons. In conclusion, we suggest that antioxidant supplementation may have a role in RTD treatment.

Colasuonno F, Niceforo A, Marioli C, Fracassi A, Stregapede F, Massey K, Tartaglia M, Bertini E, Compagnucci C, Moreno S. Mitochondrial and Peroxisomal Alterations Contribute to Energy Dysmetabolism in Riboflavin Transporter Deficiency. Oxid Med Cell Longev. 2020 Aug 12;2020:6821247. doi: 10.1155/2020/6821247. PMID: 32855765; PMCID: PMC7443020.

Abstract

Riboflavin transporter deficiency (RTD) is a childhood-onset neurodegenerative disorder characterized by progressive pontobulbar palsy, sensory and motor neuron degeneration, sensorineural hearing loss, and optic atrophy. As riboflavin (RF) is the precursor of FAD and FMN, we hypothesize that both mitochondrial and peroxisomal energy metabolism pathways involving flavoproteins could be directly affected in RTD, thus impacting cellular redox status. In the present work, we used induced pluripotent stem cells (iPSCs) from RTD patients to investigate morphofunctional features, focusing on mitochondrial and peroxisomal compartments. Using this model, we document the following RTD-associated alterations: (i) abnormal colony-forming ability and loss of cell-cell contacts, revealed by light, electron, and confocal microscopy, using tight junction marker ZO-1; (ii) mitochondrial ultrastructural abnormalities, involving shape, number, and intracellular distribution of the organelles, as assessed by focused ion beam/scanning electron microscopy (FIB/SEM); (iii) redox imbalance, with high levels of superoxide anion, as assessed by MitoSOX assay accompanied by abnormal mitochondrial polarization state, evaluated by JC-1 staining; (iv) altered immunofluorescence expression of antioxidant systems, namely, glutathione, superoxide dismutase 1 and 2, and catalase, as assessed by quantitatively evaluated confocal microscopy; and (v) peroxisomal downregulation, as demonstrated by levels and distribution of fatty acyl β-oxidation enzymes. RF supplementation results in amelioration of cell phenotype and rescue of redox status, which was associated to improved ultrastructural features of mitochondria, thus strongly supporting patient treatment with RF, to restore mitochondrial- and peroxisomal-related aspects of energy dysmetabolism and oxidative stress in RTD syndrome.

Shades of Questcor 8

I hold my nose and prescribe.

How much money does the manufacturer of Valtoco make?

The manufacturer of Valtoco, Neurelis, Inc., generated an estimated $295 million to $300 million in net sales for the full year of 2025. Because Valtoco is their flagship commercial product, it drives the vast majority of this revenue.

A breakdown of Neurelis' financial performance highlights their latest earnings structure:

Net Sales Growth: The $295–$300 million figure for 2025 represents an immense jump, more than doubling their 2024 net sales figures.

Profitability: The company reported an EBITDA margin of 30%+, meaning their core operating profitability is roughly $90 million or more before accounting for interest, taxes, depreciation, and amortization.Cash Reserves: As of December 31, 2025, Neurelis held $175+ million in cash with zero bank debt.

Growth Catalysts: Sales spiked dramatically following the FDA indication expansion allowing children ages 2 to 5 to be prescribed the nasal spray.

Google AI

______________________________________________________

Why is Valtoco so expensive?

AI Overview

Valtoco is expensive because it is a brand-name medication with no generic alternative. Its high cost reflects the years of research and clinical trials required to develop its specialized, needle-free nasal delivery system, alongside the proprietary Intravail absorption technology. 

Because it is a patented pharmaceutical manufactured by Neurelis, there are no competitors to drive down the retail price, which can easily exceed $380 to $1,000+ depending on the prescribed dosage. However, according to discussion on the r/Epilepsy Reddit Forum, users agree that the prohibitive retail prices can be bypassed using manufacturer savings programs and patient assistance programs, often bringing costs down significantly. 

Patients prescribed Valtoco can utilize several tools to reduce their out-of-pocket costs: 

Manufacturer Co-Pay Cards: Patients with commercial insurance can often pay as little as $20 through the VALTOCO Co-Pay Card Program.

Patient Assistance Programs: Uninsured or underinsured patients may qualify to receive the medication at no cost through the myNEURELIS Support Program.

Discount Cards: Using tools like the GoodRx Valtoco Page can also provide pharmacy coupons that drop the cash price well below retail. 

Google AI

____________________________________________________________

https://www.goodrx.com/compare/valtoco-vs-nayzilam?srsltid=AfmBOoqX1pJPJOst4uJ4rSnKKPZYn5bM43xB8ft4cw03pqGiX3lfJmio

ZNF292 neurodevelopmental disorder

Inspired by a patient

Kaushik K, Chapman G, Prakasam R, Batool F, Saleh M, Determan J, Huettner JE, Kroll KL. Requirements for the neurodevelopmental disorder-associated gene ZNF292 in human cortical interneuron development and function. Cell Rep. 2025 May 27;44(5):115597. doi: 10.1016/j.celrep.2025.115597. Epub 2025 Apr 20. PMID: 40257863; PMCID: PMC12283078.

Abstract

Pathogenic mutation of the zinc-finger transcription factor ZNF292 is a recently defined contributor to human neurodevelopmental disorders (NDDs). However, the gene's roles in cortical development and regulatory networks under its control were previously undefined. Here, human stem cell models of ZNF292 deficiency, resembling pathogenic haploinsufficiency, are used to derive cortical inhibitory neuron progenitors and neurons. ZNF292-deficient progenitors undergo precocious differentiation but subsequently exhibit compromised interneuron maturation and function. In progenitors, genome-wide occupancy and transcriptomic analyses identify direct target genes controlling neuronal differentiation and synapse formation that are upregulated upon ZNF292 deficiency. By contrast, deficiency in interneurons compromises ZNF292 genome-wide association with and causes downregulation of direct target genes promoting interneuron maturation and function, including other NDD genes. ZNF292-deficient interneurons also exhibit altered channel activities, elevated GABA responsiveness, and hallmarks of neuronal hyperactivity. Together, the results of this work define neurodevelopmental requirements for ZNF292, some of which may contribute to pathogenic ZNF292 mutation-related NDDs.

Mirzaa GM, Chong JX, Piton A, Popp B, Foss K, Guo H, Harripaul R, Xia K, Scheck J, Aldinger KA, Sajan SA, Tang S, Bonneau D, Beck A, White J, Mahida S, Harris J, Smith-Hicks C, Hoyer J, Zweier C, Reis A, Thiel CT, Jamra RA, Zeid N, Yang A, Farach LS, Walsh L, Payne K, Rohena L, Velinov M, Ziegler A, Schaefer E, Gatinois V, Geneviève D, Simon MEH, Kohler J, Rotenberg J, Wheeler P, Larson A, Ernst ME, Akman CI, Westman R, Blanchet P, Schillaci LA, Vincent-Delorme C, Gripp KW, Mattioli F, Guyader GL, Gerard B, Mathieu-Dramard M, Morin G, Sasanfar R, Ayub M, Vasli N, Yang S, Person R, Monaghan KG, Nickerson DA, van Binsbergen E, Enns GM, Dries AM, Rowe LJ, Tsai ACH, Svihovec S, Friedman J, Agha Z, Qamar R, Rodan LH, Martinez-Agosto J, Ockeloen CW, Vincent M, Sunderland WJ, Bernstein JA; Undiagnosed Diseases Network,; Eichler EE, Vincent JB; University of Washington Center for Mendelian Genomics (UW-CMG),; Bamshad MJ. De novo and inherited variants in ZNF292 underlie a neurodevelopmental disorder with features of autism spectrum disorder. Genet Med. 2020 Mar;22(3):538-546. doi: 10.1038/s41436-019-0693-9. Epub 2019 Nov 14. PMID: 31723249; PMCID: PMC7060121.

Abstract

Purpose: Intellectual disability (ID) and autism spectrum disorder (ASD) are genetically heterogeneous neurodevelopmental disorders. We sought to delineate the clinical, molecular, and neuroimaging spectrum of a novel neurodevelopmental disorder caused by variants in the zinc finger protein 292 gene (ZNF292).

Methods: We ascertained a cohort of 28 families with ID due to putatively pathogenic ZNF292 variants that were identified via targeted and exome sequencing. Available data were analyzed to characterize the canonical phenotype and examine genotype-phenotype relationships.

Results: Probands presented with ID as well as a spectrum of neurodevelopmental features including ASD, among others. All ZNF292 variants were de novo, except in one family with dominant inheritance. ZNF292 encodes a highly conserved zinc finger protein that acts as a transcription factor and is highly expressed in the developing human brain supporting its critical role in neurodevelopment.

Conclusion: De novo and dominantly inherited variants in ZNF292 are associated with a range of neurodevelopmental features including ID and ASD. The clinical spectrum is broad, and most individuals present with mild to moderate ID with or without other syndromic features. Our results suggest that variants in ZNF292 are likely a recurrent cause of a neurodevelopmental disorder manifesting as ID with or without ASD.

Dongxue L, Ruen Y, Ying Y, Liting C, Jie W, Chunjiao L, Wei L, Rikun C, Cuiyun L. Short Stature and Developmental Delay Associated With a Novel Frame-Shift Mutation in ZNF292: Case Report and Literature Review. Clin Case Rep. 2025 Aug 7;13(8):e70747. doi: 10.1002/ccr3.70747. PMID: 40777882; PMCID: PMC12329236.

Abstract

Pathogenic mutations in the ZNF292 gene are a significant genetic cause of Intellectual Developmental Disorder (IDD) in individuals, manifesting with a spectrum of clinical features including mild to severe intellectual impairment, speech delay, and co-occurring autism spectrum disorder (ASD). In this study, we present a novel clinical phenotype associated with a newly identified variant of ZNF292 and conduct a thorough review of relevant literature. A 4-year-old female patient displayed language developmental delays, short stature, and skeletal abnormalities. Trio whole-exome sequencing revealed a novel de novo heterozygous frameshift variant in exon 8 of the ZNF292 gene, c.5977_5978del, p.Gln1993fs. According to the ACMG guidelines, this variant is expected to be pathogenic. Our research unveils a novel variant in ZNF292-related disorders and expands the associated phenotypic spectrum. This study highlights the significance of employing next-generation sequencing for timely patient diagnosis, while further clinical phenotypic and genotypic investigations could improve the understanding of ZNF292-linked conditions.

Wang F, Qi N, Gao Y, Wu D, Zhang M, Zhang Q, Yang K, Peng H, Lei X, Liao S. [Genetic analysis of two children with developmental delay and intellectual disability]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2023 Jul 10;40(7):876-880. Chinese. doi: 10.3760/cma.j.cn511374-20220318-00181. PMID: 37368394.

Abstract

Objective: To explore the genetic etiology of two patients with developmental delay and intellectual disability.

Methods: Two children who were respectively admitted to Henan Provincial People's Hospital on August 29, 2021 and August 5, 2019 were selected as the study subjects. Clinical data were collected, and array comparative genomic hybridization (aCGH) was carried out on the children and their parents for the detection of chromosomal microduplication/microdeletions.

Results: Patient 1 was a 2-year-and-10-month female and patient 2 was a 3-year-old female. Both children had featured developmental delay, intellectual disability, and abnormal findings on cranial MRI. aCGH revealed that patient 1 has harbored arr[hg19] 6q14.2q15(84621837_90815662)×1, a 6.19 Mb deletion at 6q14.2q15, which encompassed ZNF292, the pathogenic gene for Autosomal dominant intellectual developmental disorder 64. Patient 2 has harbored arr[hg19] 22q13.31q13.33(46294326_51178264)×1, a 4.88 Mb deletion at 22q13.31q13.33 encompassing the SHANK3 gene, haploinsufficiency of which can lead to Phelan-McDermid syndrome. Both deletions were classified as pathogenic CNVs based on the guidelines of American College of Medical Genetics and Genomics (ACMG) and were not found in their parents.

Conclusion: The 6q14.2q15 deletion and 22q13-31q13.33 deletion probably underlay the developmental delay and intellectual disability in the two children, respectively. Haploinsufficiency of the ZNF292 gene may account for the key clinical features of the 6q14.2q15 deletion.

MOGAD — An emerging disease: Q&A

MOGAD — An Emerging Disease: Q&A with a Pediatric Neurologist

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare neuroimmune condition that affects the brain, eyes and spine. Though it shares similarities with other diseases, it was recently classified as its own disease after information distinguishing it from other conditions was discovered.

Brenda Banwell, M.D., a pediatric neurologist and pediatrician-in-chief at Johns Hopkins Children’s Center, has studied the disease for years, and co-created the Pediatric Multiple Sclerosis, MOGAD and Neuroimmune Disorders Program. She answers common questions about the condition.

Key Points

MOGAD is a rare condition that occurs when the immune system attacks the brain, the nerves connected to the eyes and the spinal cord.

It's unclear how prevalent MOGAD is because diagnostic criteria were recently established.

Children or adults with a diagnosis of MOGAD should be referred to a neurologist with understanding of the condition.

Johns Hopkins has a team of internationally recognized leaders in pediatric neuroimmunology and an established program for treating MOGAD.

What is MOGAD?

Myelin oligodendrocyte glycoprotein antibody-associated disease, more commonly called MOGAD, is a condition that affects children and adults in which the immune system attacks the brain, the nerves connected to the eyes and the spinal cord.

What are the common symptoms of MOGAD?

Vision loss is the most common symptom. A person will also have some pain during eye movement.

Spinal cord attack is another common symptom. This involves numbness, tingling or weakness in the arms and legs, depending on the level of the spinal cord involvement. If the lower part of the spinal cord is involved, patients may have difficulty passing urine and have symptoms of loss of bladder control.

Acute disseminated encephalomyelitis (ADEM) is the third-most common symptom. With ADEM, a person experiences confusion, often along with:

confusion, lack of awareness or, in extreme cases, coma

limb weakness

visual impairment

lack of balance while walking

What are the differences between the symptoms in MOGAD and Multiple Sclerosis (MS)?

To the best of our knowledge, MOGAD shows no symptoms before the first attack. Patients I speak with don’t have any symptoms that occur in the weeks leading up to their first attack.

MS is different. People who don’t know they have MS until their first attack will often tell me they are more tired than their friends, or that their hand went numb for a couple of days, or they couldn’t see well in one eye, but it got better over a week or two.

These observations tell me that MS starts way before the first attack, whereas MOGAD seems to start near the time of attack.

How common is MOGAD?

We don't know yet how common MOGAD is. That’s because the criteria for making a MOGAD diagnosis were published in 2023, and many clinicians around the world are just now applying them and identifying children and adults who meet them.

Also, the diagnosis of MOGAD requires the detection of antibodies or proteins in the bloodstream that target myelin oligodendrocyte glycoprotein (MOG). This testing has become reliably available in only about the last five years, and it's still not easily accessible in many parts of the world.

What treatment options are available for MOGAD?

The treatment of MOGAD depends on whether it is a patient’s first symptomatic event or a relapse.

First Event: This is when we treat the patient immediately when they come in with the first event of visual loss, confusion or spinal cord symptoms.

Treatment with high-dose corticosteroids typically works quickly and reduces inflammation in the brain, the optic nerves or the spinal cord.

If that's not enough, we move to other therapies, often using plasma exchange. In this therapy, we take those MOG antibodies we believe are contributing to the symptoms out of blood circulation — like a dialysis for the bloodstream.

We also use intravenous immunoglobulin (IVIG), which introduces antibodies from healthy donors into the blood through IV and can help neutralize the MOG antibodies and reduce inflammation while suppressing the immune system.

In addition to that, we can also use tocilizumab or a similar medicine, which is an immunosuppressant that can be lifesaving for someone having a severe MOGAD attack.

Relapsing MOGAD: The second treatment instance is for people who experience relapsing MOGAD, and we want to prevent those relapses.

We can use IVIG, but in a monthly dose.

Sometimes, we use rituximab, an antibody therapy that blocks one particular part of the immune system that triggers the relapse.

At this point, there are no specific treatments for MOGAD that have been approved through the typical regulatory process — by the Food and Drug Administration in the United States, and by the European Medicines Agency in Europe. All therapies right now are guided by specialists that have worked as a community to provide guidelines for the treatment of MOGAD.

Will all people with MOGAD have a relapse?

Not all patients will have a relapsing form of MOGAD. Some people will have one attack, and that appears to be the entire experience they have with MOGAD.

Is MOGAD more commonly seen in children or adults?

MOGAD is probably more common in children. That might change as more adult care providers start to recognize more people with MOGAD because we now have the ability to test for the antibody and use the diagnostic criteria.

What kind of doctor should a person diagnosed with MOGAD see for care?

Anyone with a diagnosis of MOGAD should be referred to either a child or adult neurologist who understands this condition. MOGAD is rare and there are many doctors around the world who would not be familiar with its diagnosis and/or the different treatments and the strategies to manage the condition.

What is the long-term outlook for people diagnosed with MOGAD?

Most patients with MOGAD do well. I can also share that relapsing MOGAD is generally a much more serious condition than cases of one event. When you have relapsing MOGAD, you're most likely going to experience new attacks in the eye, leading to loss of vision. But with current therapies, we seem to be doing better at suppressing those attacks than we were 20 years ago.

With proper therapy, most of my patients are doing very well, but what I don't know is how they will be doing in 10 or 20 years. We’re going to need to work as a community to figure that out in this era of prompt diagnosis and available treatment.

https://www.hopkinsmedicine.org/health/expert-qa/mogad-q-and-a?

Is cardiac death death?

Arizona police have recommended felony child abuse charges against the parents of an 18-month-old boy who investigators say nearly drowned after they admitted using marijuana and failed to properly supervise him during a Super Bowl party earlier this year. The child later drew national attention after he was mistakenly declared dead before being found alive hours later in a hospital morgue.

The Maricopa County Attorney's Office is reviewing the Gilbert Police Department's recommendation that Vincent Fiordilino's parents face felony child abuse charges, according to AZFamily. No charges have been filed.

Investigators say Vincent disappeared from his parents' view during the gathering before guests found him floating face down in a backyard swimming pool. According to a police report obtained by AZFamily, both parents later admitted to smoking marijuana during the party. The report alleges Vincent's fall into the pool went unnoticed because both parents were impaired by marijuana and/or other mind-altering substances.

After Vincent was pulled from the water, first responders transported him to Mercy Gilbert Medical Center, where a doctor pronounced him dead that evening, according to police. The case took an extraordinary turn hours later when medical personnel discovered the toddler was alive and breathing after he had already been transferred to the hospital's morgue around 7:23 p.m., according to police. Vincent was immediately airlifted to Phoenix Children's Hospital for treatment.

The police report alleges responding officers and Vincent's parents questioned whether the toddler had actually died before he was pronounced dead, saying they believed he was still showing signs of life. Hospital staff reportedly told them Vincent was exhibiting agonal breathing, an involuntary reflex that can occur near death.

According to the report, a nurse later reported detecting a pulse after the child had been pronounced dead. Detectives allege the physician who made the initial determination maintained his assessment was correct and instructed hospital staff to stop lifesaving measures despite concerns from Vincent's parents and responding officers that the toddler still appeared to be breathing. Police did not recommend criminal charges against the physician, according to AZFamily.

According to AZFamily, a Dignity Health spokesperson said the hospital conducted a review following the incident.

"This is a heartbreaking situation. We immediately conducted a thorough review of all aspects of the care that was provided to learn what happened and to make meaningful changes to strengthen our care," the spokesperson said in a statement. "Out of respect for the patient's privacy, we cannot discuss details. We continue to work with the family and their representative. Patient safety and exceptional care is our highest priority."

A GoFundMe campaign created for the family described Vincent as a "miracle baby" after he survived the ordeal.

"Vincent was declared deceased," the fundraiser says. "His devastated parents were sent home in unimaginable grief. But God had other plans. A little after 11:30 p.m., the family received a call no one expected: the medical examiner had detected a faint heartbeat."

According to the fundraiser, Vincent's kidneys, lungs and liver began shutting down after he arrived at Phoenix Children's Hospital. An MRI initially identified two small areas of potential brain damage, but later testing reportedly found no brain damage. The fundraiser says Vincent continues to require extensive therapy, ongoing medical monitoring and treatment as he recovers.

Fox News Digital has reached out to the Maricopa County Attorney's Office, Gilbert Police Department, Mercy Gilbert Medical Center and Phoenix Children's Hospital for comment.

Brittany Miller

https://www.foxnews.com/us/toddler-declared-dead-after-near-drowning-found-alive-hospital-morgue-hours-later-police-say

Human rabies

An 11-year-old boy died of a rabies infection in Ontario, Canada, according to a medical journal article published Monday.

The Canadian Medical Association Journal did not identify the boy or his family but wrote that he was first brought to a hospital weeks after an encounter with a bat.

"The patient’s family reported that, during a visit to a cottage in northern Ontario 19 days before symptom onset, the boy had been awoken by a bat on his nose and mouth. He had swatted the bat off his face; his father had caught the bat in a cooking pot and released it outside," CMAJ wrote.

"The child had no visible lesions on his face, and his parents did not consider that the bat had behaved erratically. Therefore, they did not seek medical assessment," the journal noted.

The boy was ultimately admitted to a hospital 20 days after the encounter with the bat, when his parents brought him to an emergency room. He was first sent home but then brought back the following morning and admitted to the hospital.

Doctors noted that the boy's condition "rapidly worsened" by the evening, but he spent more than two weeks in the hospital before dying.

"By day 5 of admission, his brainstem reflexes were absent. Life-sustaining therapies were withdrawn on day 17 of admission, and he died peacefully with his family at his bedside," the journal article said.

Doctors who authored the article warned that any direct human contact with a bat, even in the absence of a visible bite or scratch, should be discussed with public health authorities.

Rabies is almost always fatal in humans if not treated quickly with postexposure prophylaxis, or PEP. The treatment is nearly always successful if administered promptly after exposure.

Anders Hagstrom

https://www.foxnews.com/world/11-year-old-dies-rabies-bat-landed-face-sleeping

Padmaja Sreeram, Neha Saini, Karen Choong, Ellery Cunan, Alan C. Jackson, Jeffrey M. Pernica

and Brian Hummel. Fatal rabies in a child. CMAJ June 29, 2026 198(25) E969-E972;
DOI: https://doi.org/10.1503/cmaj.251933